State Key Laboratory of Metastable Materials Science and Technology, Applying Chemistry Key Lab of Hebei Province, Hebei Key Laboratory of Heavy Metal Deep-remediation in Water and Resource Reuse , Yanshan University , Qinhuangdao 066004 , P. R. China.
ACS Appl Mater Interfaces. 2020 Feb 26;12(8):8978-8988. doi: 10.1021/acsami.9b20062. Epub 2020 Feb 17.
Cells in the center of solid tumors have always been an abyss untouched by treatments because of their deep location and increased drug resistance. Herein, we designed a rational strategy for sequential intra-intercellular delivery of nanomedicine to deep sites of drug-resistant solid tumors. In our formulation, dopamine and hemoglobin were polymerized to form a smart nanocarrier (PDA/Hb). Subsequently, the doxorubicin and nitric oxide donor were connected on the surface of PDA/Hb to obtain D/N-PDA/Hb. Ultimately, the hyaluronic acid was combined with D/N-PDA/Hb to form D/N-PDA/Hb@HA. Concretely, acidic and neutral environments of tumor cells were treated as a switch to turn on or off the drug release of a nanodrug. Meanwhile, the generation of nitric oxide in situ was exploited to favor the lysosomal escape of nanocarriers and overcome the drug resistance of deep solid tumor cells. The results indicated that the nanodrug based on sequential intra-intercellular delivery showed exciting penetration efficiency and resistance reversal of solid tumors. Conventional nanodrug delivery was highly dependent on the enhanced permeability and retention (EPR) effect and limited by tumorous interstitial fluid pressure. Plenty of drugs stayed on the surface of solid tumors, and the infiltrated drugs were inefficient due to strict resistance. To conquer this dilemma, this work proposed a new mechanism reversing the EPR effect for drug delivery, leading to better penetration and resistance reversal of solid tumors.
由于其位置较深和耐药性增加,实体瘤中心的细胞一直是治疗方法无法触及的深渊。在此,我们设计了一种合理的策略,用于顺序向耐药性实体瘤的深部部位递送电镜下可观察到的细胞内和细胞间纳米药物。在我们的配方中,多巴胺和血红蛋白聚合形成智能纳米载体(PDA/Hb)。随后,将阿霉素和一氧化氮供体连接到 PDA/Hb 表面,得到 D/N-PDA/Hb。最终,透明质酸与 D/N-PDA/Hb 结合形成 D/N-PDA/Hb@HA。具体来说,肿瘤细胞的酸性和中性环境被用作开关,以开启或关闭纳米药物的释放。同时,原位生成的一氧化氮被利用来促进纳米载体的溶酶体逃逸,并克服深部实体瘤细胞的耐药性。结果表明,基于顺序细胞内和细胞间递药的纳米药物显示出令人兴奋的实体瘤穿透效率和耐药逆转。传统的纳米药物递送高度依赖于增强的渗透性和保留(EPR)效应,并受到肿瘤间质液压力的限制。大量药物停留在实体瘤表面,由于严格的耐药性,渗透的药物效率低下。为了克服这一困境,这项工作提出了一种用于药物递送的逆转 EPR 效应的新机制,导致更好的穿透和耐药性逆转实体瘤。
ACS Appl Mater Interfaces. 2020-2-17
Drug Deliv Transl Res. 2024-7
Signal Transduct Target Ther. 2022-12-2
J Nanobiotechnology. 2022-6-25
Pharmaceutics. 2021-6-8
Signal Transduct Target Ther. 2020-11-6